French biotechnology company Transgene (Euronext Paris:TNG) revealed on Monday that its randomised Phase II study evaluating TG4001 in combination with avelumab for recurrent or metastatic HPV16-positive cervical and anogenital tumours did not meet its primary objective of improving progression-free survival.
While the primary endpoint was not met, a pre-planned subgroup analysis showed a positive efficacy trend in favour of the TG4001-containing regimen in cervical cancer patients.
Transgene will now conduct a thorough analysis of the data to determine the optimal path forward for TG4001, in particular in cervical cancer.
Despite the primary objective not being met, the treatment was well-tolerated, with adverse events consistent with previous observations.
Transgene plans to present the complete study results at a future scientific conference.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial